(Q44127880)

English

Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Shahin Akhondzadeh

9

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Ali Ghaleiha

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Effat Mohammadi

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Mohammad-Reza Mohammadi

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Mehdi Farokhnia

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Amirhossein Modabbernia

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Habibeh Yekehtaz

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Mandana Ashrafi

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Elmira Hassanzadeh

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Pediatric Drugs

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

505-514

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Identification and Evaluation of Children With Autism Spectrum Disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Immunological findings in autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Searching for ways out of the autism maze: genetic, epigenetic and environmental clues

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Neurotransmitters and brain maturation: early paracrine actions of GABA and glutamate modulate neuronal migration

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Neurotransmitters and vulnerability of the developing brain

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

The hyperglutamatergic hypothesis of autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Increased serum levels of glutamate in adult patients with autism.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Linkage and association of the glutamate receptor 6 gene with autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

The genetics of autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Riluzole enhances glutamate uptake in rat astrocyte cultures

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

The pharmacology and mechanism of action of riluzole

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Interacting partners of AMPA-type glutamate receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Postmortem brain abnormalities of the glutamate neurotransmitter system in autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Alteration of plasma glutamate and glutamine levels in children with high-functioning autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Riluzole in psychiatry: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Obsessive compulsive behaviour in autism--towards an autistic-obsessive compulsive syndrome?

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Increase in valproic acid levels during riluzole treatment in an adolescent with autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Riluzole in autistic disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

A systematic review of medical treatments for children with autism spectrum disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

The NMDA receptor as a target for cognitive enhancement

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

A review of autism and the immune response

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Neuroglial activation and neuroinflammation in the brain of patients with autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Brain-derived neurotrophic factor and neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Long-term safety of riluzole in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0036-2

21 January 2018

Rating scales and checklists for child psychopharmacology.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821414

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40272-013-0036-2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44127880&oldid=2206451500"